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Ribonuclease L (RNase L) is an important effector of the innate antiviral response. Mutations or variants that impair
function of RNase L, particularly R462Q, have been proposed as susceptibility factors for prostate cancer. Given the
role of this gene in viral defense, we sought to explore the possibility that a viral infection might contribute to prostate
cancer in individuals harboring the R462Q variant. A viral detection DNA microarray composed of oligonucleotides
corresponding to the most conserved sequences of all known viruses identified the presence of gammaretroviral
sequences in cDNA samples from seven of 11 R462Q-homozygous (QQ) cases, and in one of eight heterozygous (RQ)
and homozygous wild-type (RR) cases. An expanded survey of 86 tumors by specific RT-PCR detected the virus in eight
of 20 QQ cases (40%), compared with only one sample (1.5%) among 66 RQ and RR cases. The full-length viral genome
was cloned and sequenced independently from three positive QQ cases. The virus, named XMRV, is closely related to
xenotropic murine leukemia viruses (MuLVs), but its sequence is clearly distinct from all known members of this group.
Comparison of gag and pol sequences from different tumor isolates suggested infection with the same virus in all
cases, yet sequence variation was consistent with the infections being independently acquired. Analysis of prostate
tissues from XMRV-positive cases by in situ hybridization and immunohistochemistry showed that XMRV nucleic acid
and protein can be detected in about 1% of stromal cells, predominantly fibroblasts and hematopoietic elements in
regions adjacent to the carcinoma. These data provide to our knowledge the first demonstration that xenotropic
MuLV-related viruses can produce an authentic human infection, and strongly implicate RNase L activity in the
prevention or clearance of infection in vivo. These findings also raise questions about the possible relationship
between exogenous infection and cancer development in genetically susceptible individuals.
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Introduction
Type I interferons (IFNs) are rapidly mobilized in response
to viral infection and trigger potent antiviral responses. One
such response is the induction by IFN of a family of 2959
oligoadenylate synthetases (OAS); upon activation by virally
encoded dsRNA, these enzymes produce 59-phosphorylated
29-59 linked oligoadenylates (2–5A) from ATP [1]. 2–5A, in
turn, is an activator of ribonuclease L (RNase L) [2], which
degrades viral (and cellular) single stranded RNAs [3]. In vivo
evidence for the antiviral role of the 2–5A system was
provided by studies with RNase L
 /  mice, which have
enhanced susceptibility to infections by the picornaviruses,
encephalomyocarditis virus, and Coxsackievirus B4 [4,5].
Ultimately, sustained activation of RNase L triggers a
mitochondrial pathway of apoptosis that eliminates virus-
infected cells [4,6–8]. Genetic lesions in RNase L impair this
apoptotic response, which has raised interest in the possi-
bility that such mutations might also contribute to malig-
nancy [9].
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mutations in RNase L to prostate cancer susceptibility [10–
13]. Prostate cancer has a complex etiology inﬂuenced by
androgens, diet, and other environmental and genetic factors
[14]. While sporadic prostate cancer displays an age-related
increase in prevalence, familial prostate cancer kindreds
often display early-onset disease. Such kindreds, deﬁned by
having more than three affected members per family, account
for 43% of early onset cases (,55 years old) and 9% of all
cases [15]. The genetics of hereditary prostate cancer (HPC) is
complex, and several genes have been proposed as suscept-
ibility factors in this syndrome. Interestingly, one of these,
HPC1, is linked to RNASEL [10,11]. Several germline
mutations or variants in HPC1/RNASEL have been observed
in HPC [10–13] (reviewed in [16]), including a common (35%
allelic frequency) missense variant of RNase L, in which a G to
A transition at nucleotide (nt) position 1385 (G1385A) results
in a glutamine instead of arginine at amino acid position 462
(R462Q). Remarkably, a large, controlled sib-pair study
implicated the R462Q RNase L variant in up to 13% of
unselected prostate cancer cases [11]. One copy of the
mutated gene increased the risk of prostate cancer by about
50%, whereas individuals that were homozygous for the
mutation had a 2-fold increased risk of prostate cancer. The
R462Q RNase L variant had a 3-fold decrease in catalytic
activity compared with the wild-type enzyme [9,11]. However,
while several case-controlled genetic and epidemiologic
studies support the involvement of RNASEL (and notably
the R462Q variant) in prostate cancer etiology [10–13], others
do not [17–19], suggesting that either population differences
or environmental factors may modulate the impact of
RNASEL on prostatic carcinogenesis.
While the antiapoptotic phenotype of RNase L deﬁciency
has dominated previous discussions of its possible linkage to
cancer, RNase L is also a key effector of the antiviral action of
interferons. This led us to consider the possibility that the
putative linkage of RNase L alterations to HPC might reﬂect
enhanced susceptibility to a viral agent. To test this
hypothesis, we have examined RNA derived from wild-type
and RNase L variant (R462Q) prostate tumors for evidence of
viral sequences, by hybridization to a DNA microarray
composed of the most conserved sequences of all known
human, animal, plant, and bacterial viruses [20,21]. Here we
report that 40% (eight of 20) of all tumors homozygous for
t h eR 4 6 2 Qa l l e l eh a r b o r e dt h eg e n o m eo fad i s t i n c t
gammaretrovirus closely related to xenotropic murine
leukemia viruses (MuLVs). In contrast, retroviral sequences
were present in ,2% of tumors bearing at least one copy of
the wild-type allele (one of 66). In addition, virus-harboring
cells were detected within infected prostatic tumor tissues by
ﬂuorescence in situ hybridization (FISH) and immunohisto-
chemistry (IHC). These ﬁndings represent the ﬁrst detection
of xenotropic MuLV–like agents in humans, and reveal a
strong association between infection with the virus and
defects in RNase L activity. The relation of retroviral
infection to prostate cancer will require further study, but a
cofactor role is not excluded.
Results
Detection of XMRV by Microarray-Based Screening
To search for potential viruses in prostate cancer tumors,
we employed a DNA microarray-based strategy designed to
screen for viruses from all known viral families [20,21]. Total
or polyadenylated RNA extracted from tumor tissue was ﬁrst
ampliﬁed and ﬂuorescently labeled in a sequence-nonspeciﬁc
fashion. The ampliﬁed and labeled fragments, which con-
tained host as well as potential viral sequences, were then
hybridized to a DNA microarray (Virochip, University of
California San Francisco, San Francisco, United States)
bearing the most conserved sequences of ;950 fully
sequenced NCBI reference viral genomes (;11,000 70-mer
oligonucleotides).
The Virochip was used to screen RNA samples isolated
from prostate tumors of 19 individuals (Figure 1). A positive
hybridization signal suggestive of a gammaretrovirus was
detected in seven of 11 tumors from patients homozygous for
the R462Q RNASEL variant (QQ). In contrast, no virus was
detected in three tumors from RQ heterozygotes, and only
one of ﬁve tumors from RR individuals was positive.
Clustering of the microarray oligonucleotide intensities
(Figure 1) revealed a similar hybridization pattern in all
positive cases. Furthermore, a computational analysis using E-
Predict, a recently described algorithm for viral species
identiﬁcation [22], suggested that the same or similar
mammalian gammaretrovirus was present in all positive
tumors (Table S1). Thus, the Virochip detected the presence
of a probable gammaretrovirus in half of the QQ tumor
samples and in only one non-QQ sample.
Characterization of XMRV Genome
To further characterize the virus, we recovered its entire
genome from one of the tumors (VP35) (Figure 2). To obtain
viral clones, we ﬁrst employed a direct microarray recovery
technique described previously [21]. Brieﬂy, ampliﬁed nucleic
acid from the tumor tissue, which hybridized to viral
microarray oligonucleotides, was eluted from two speciﬁc
spots. The eluted DNA was re-ampliﬁed, and plasmid libraries
constructed from this material were screened by colony
hybridization using the spots’ oligonucleotides as probes. The
array oligonucleotides used in this case derived from the LTR
region of murine type C retrovirus (MTCR) and spleen focus-
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Synopsis
Prostate cancer is the most frequent cancer and the second leading
cause of cancer deaths in US men over the age of 50. Several genetic
factors have been proposed as potential risk factors for the develop-
mentofprostatecancer,includingaviraldefensegenecalledRNASEL.
A common genetic variant in this gene, R462Q, was recently
implicated in up to 13% of prostate cancer cases. Given the antiviral
role of RNASEL, the authors sought to examine if a virus might be
presentinprostatecancersassociatedwiththeR462Qvariant.Usinga
DNA microarray designed to detect all known viral families, the
authors identified a novel virus, named XMRV, in a subset of prostate
tumor samples. Polymerase chain reaction testing of 86 prostate
tumors for the presence of XMRV revealed a strong association
between the presence of the virus and being homozygous for the
R462Q variant. Cloning and sequencing of the virus showed that
XMRV is a close relativeof severalknownxenotropic murineleukemia
viruses. This report presents the first documented cases of human
infection with a xenotropic retrovirus. Future work will address the
potential connection between XMRV infection and the increased
prostate cancer risk in patients with the R462Q RNASEL variant.forming virus (SFFV) [23]. The largest recovered fragment was
415 nt in length, and had 96% nt identity to the LTR region
of MTCR, a MuLV identiﬁed in the genome of a mouse
myeloma cell line (T. Heinemeyer, unpublished data). These
ﬁndings established that the virus in question was indeed a
gammaretrovirus, and likely a relative of MuLVs. To clone
and sequence the rest of the viral genome from sample VP35,
we used tumor cDNA to PCR-amplify overlapping segments
using primers derived from MTCR; gaps were closed using
primers from earlier recovered clones (Figure 2B and Table
S2). Using a similar strategy, we have also determined the full
sequence of the virus from a second tumor, VP42. Finally, a
complete viral genomic sequence from a third tumor case,
VP62, was obtained by PCR ampliﬁcation of two ;4 Kb–long
overlapping fragments jointly spanning close to the entire
length of the virus (Figure 2B). The three sequenced genomes
share .98% nt identity overall and .99% amino acid (aa)
identity for predicted open reading frames (ORFs), and thus
represent the same virus.
The full genome of the virus (Figures 2 and S1) is 8,185 nt
long and is distinct from all known isolates of MuLV. The
genome is most similar to the genomes of exogenous MuLVs,
DG-75 cloned from a human B-lymphoblastoid cell line [24],
and MTCR, with which it shares 94% and 93% overall nt
sequence identity, respectively. The genome also shares up to
95% nt identity with several full-length Mus musculus
endogenous proviruses (Figure 2C). Phylogenetic trees con-
structed using available mammalian type C retroviral
genomes and representative full-length proviral sequences
from the mouse genome (Figures 3 and S2) showed that the
newly identiﬁed virus is more similar to xenotropic and
polytropic than to ecotropic genomes. Based on these
ﬁndings we propose the provisional name Xenotropic
MuLV-related virus (XMRV) for this agent.
Translation of the XMRV genomic sequence using ORF
Finder [25] identiﬁed two overlapping ORFs coding for the
full-length Gag-Pro-Pol and Env polyproteins. No exogenous
coding sequences, such as viral oncogenes, could be detected
in the XMRV genome. The predicted Gag polyprotein is 536
aa long and is most similar to a xenotropic provirus on M.
musculus Chromosome 9, with which it shares 97% aa identity
(Figure S2A). The Pro-Pol polyprotein is 1,197 aa long and
has the highest aa identity with MuLV DG-75 and a
xenotropic provirus on M. musculus Chromosome 4, 97%
and 96%, respectively (Figure S2B). An amber (UAG) stop
codon separates the Gag and Pro-Pol coding sequences,
analogous to other MuLVs in which a translational read-
through is required to generate the full-length Gag-Pro-Pol
polyprotein (reviewed in [26]).
Similar to other MuLVs [23,24,27–31], the Env polyprotein
of XMRV is in a different reading frame compared with Gag-
Pro-Pol. The Env protein sequence is 645 aa long, and has the
highest amino acid identity with the Env protein of an
infectious MuLV isolated from a human small cell lung cancer
line NCI-417 [32] and MuLV New Zealand Black 9–1
xenotropic retrovirus (NZB-9–1) [28]), 95% and 94%,
respectively. The XMRV Env protein also shares similarly
high identity with several murine xenotropic proviruses
Figure 1. XMRV Detection by DNA Microarrays and RT-PCR
(A) Virochip hybridization patterns obtained for tumor samples from 19 patients. The samples (x-axis) and the 502 retroviral oligonucleotides present on
the microarray (y-axis) were clustered using hierarchical clustering. The red color saturation indicates the magnitude of hybridization intensity.
(B) Magnified view of a selected cluster containing oligonucleotides with the strongest positive signal. Samples from patients with QQ RNASEL genotype
are shown in red, and those from RQ and RR individuals as well as controls are in black.
(C) Results of nested RT-PCR specific for XMRV gag gene. Amplified gag PCR fragments along with the corresponding human GAPDH amplification
controls were separated by gel electrophoresis using the same lane order as in the microarray cluster.
DOI: 10.1371/journal.ppat.0020025.g001
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204) and acceptor (CACTTACAG, position 5,479) sites
involved in the generation of env subgenomic RNAs [33]
were found in the same relative locations as in other MuLV
genomes. A multiple sequence alignment of XMRV Env and
corresponding protein sequences of other representative
MuLVs (Figure 4) showed that within three highly variable
regions (VR), VRA, VRB, and VRC, known to be important for
cellular tropism [34–36], XMRV has the highest aa identity
with xenotropic envelopes from MuLVs NZB-9–1, NFS-Th-1
[37], and DG-75. Although unique-to-XMRV aa are present in
each of the three VRs, based on the overall similarity to the
known xenotropic envelopes, we predict that the cellular
receptor for XMRV is XPR1 (SYG1), the recently identiﬁed
receptor for xenotropic and polytropic MuLVs [38–40].
The long terminal repeat (LTR) of XMRV is 535 nt long and
has the highest nt identity with the LTRs from xenotropic
MuLVs NFS-Th-1 (96%) and NZB-9–1 (94%). The XMRV
LTRs contain known structural and regulatory elements
typical of other MuLV LTRs [33,41]. In particular, the CCAAT
box, TATAAAA box, and AATAAA polyadenylation signal
sequences were found in U3 at their expected locations
(Figure S3A). U3 also contains a glucocorticoid response
element sequence AGA ACA GAT GGT CCT. Essentially
identical sequences are present in genomes of other MuLVs.
These elements have been shown to activate LTR-directed
transcription and viral replication in vitro in response to
various steroids including androgens [42–45]. In addition,
presence of an intact glucocorticoid response element is
thought to be the determinant of higher susceptibility to FIS-
2 MuLV infection in male compared with female NMRI mice
[46,47]. Despite these similarities, single nt substitutions
unique to XMRV and an insertion of an AG dinucleotide
immediately downstream from the TATA box are present in
U3 (Figure S3A). Consistent with these ﬁndings, a phyloge-
netic analysis based on U3 sequences from XMRV and from
representative xenotropic MuLV provirus groups [48,49]
showed that XMRV U3 sequences formed a well-separated
cluster most similar to the group containing NFS-Th-1 and
NZB-9–1 (Figure S3B).
The 59 gag leader of XMRV, deﬁned as the sequence
extending from the end of U5 to the ATG start codon of gag,
consists of a conserved non-coding region of ;200 nt,
containing a proline tRNA primer binding site as well as
sequences required for viral packaging [50,51] and the
initiation of translation [52,53]. The non-coding region is
followed by a ;270-nt region extending from the conserved
CTG alternative start codon of gag. This region represents the
Figure 2. Complete Genome of XMRV
(A) Schematic map of the 8185 nt XMRV genome. LTR regions (R, U5, U3) are indicated with boxes. Predicted open reading frames encoding Gag, Gag-
Pro-Pol, and Env polyproteins are labeled in green. The corresponding start and stop codons (AUG, UAG, UGA, UAA) as well as the alternative Gag start
codon (CUG) are shown with their nt positions. Similarly, splice donor (SD) and acceptor (SA) sites are shown and correspond to the spliced 3.2-Kb Env
subgenomic RNA (wiggled line).
(B) Cloning and sequencing of XMRV VP35 and VP62 genomes. Clones obtained by probe recovery from hybridizing microarray oligonucleotides (blue
bar) or by PCR from tumor cDNA (black bars) were sequenced. Primers used to amplify individual clones (Table S2) were derived either from the
genome of MTCR (black arrows) or from overlapping VP35 clones (blue arrows).
(C) Genome sequence similarity plots comparing XMRV VP35 with XMRV VP42, XMRV VP62, MuLV DG-75, MTCR, and a set of representative non-
ecotropic proviruses (mERVs) (see Materials and Methods). The alignments were made using AVID [81], and plots were generated using mVISTA [82]
with the default window size of 100 nt. Y-axis scale for each plot represents percent nt identities from 50% to 100%. Sequences are labeled as
xenotropic (X), polytropic (P), or modified polytropic (Pm).
DOI: 10.1371/journal.ppat.0020025.g002
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MuLVs (Figures 5 and 2C). Unlike ecotropic MuLVs, where
translation from this codon adds an ;90 aa N-terminal leader
peptide in frame with the rest of the Gag protein, thus
generating a glycosylated form of Gag [54], XMRV has a stop
codon 53 aa residues downstream from the alternative start.
Interestingly, both MuLV DG-75 and MTCR gag leader
sequences are also interrupted by stop codons, and therefore
are not expected to produce full-length glyco-Gag. Further-
more, a characteristic 24-nt deletion was present in this
region of the XMRV genome, which is not found in any
known exogenous MuLV isolate. However, a shorter deletion
of nine nt internal to this region is present in the sequences
of several non-ecotropic MuLV proviruses found in the
sequenced mouse genome (Figure 5). In cell culture,
expression of intact glyco-Gag is not essential for viral
replication [55,56]. However, lesions in this region have been
associated with interesting variations in pathogenetic proper-
ties in vivo [57–61]. For example, an alteration in ten nt
affecting ﬁve residues in the N-terminal peptide of glyco-Gag
was found to be responsible for a 100-fold difference in the
frequency of neuroinvasion observed between CasFrKP and
CasFrKP41 MuLV strains [62]. In addition, insertion of an
octanucleotide resulting in a stop codon downstream of the
CUG start codon prevented severe early hemolytic anemia
and prolonged latency of erythroleukemia in mice infected
with Friend MuLV [58]. While we do not yet know the
pathogenetic signiﬁcance of the lesions in XMRV glyco-Gag,
the high degree of sequence divergence suggests that this
region may be under positive selective pressure and therefore
may be relevant to the establishment of infection within the
human host.
Association of XMRV Infection and R462Q RNASEL
Genotype
To further examine the association between presence of
the virus and the R462Q (1385G-.A) RNASEL genotype, we
developed a speciﬁc nested RT-PCR assay based on the virus
Figure 3. Phylogenetic Analysis of XMRV Based on Complete Genome
Sequences
Complete genomes of XMRV VP35, VP42, and VP62 (red); MTCR; MuLVs
DG-75, AKV, Moloney, Friend, and Rauscher; feline leukemia virus (FLV);
koala retrovirus (KoRV); gibbon ape leukemia virus (GALV); and a set of
representative non-ecotropic proviruses (mERVs) were aligned using
ClustalX (see Materials and Methods). An unrooted neighbor-joining tree
was generated based on this alignment, excluding gaps and using
Kimura’s correction for multiple base substitutions. Bootstrap values (n¼
1000 trials) are indicated as percentages. Sequences are labeled as
xenotropic (X), polytropic (P), modified polytropic (Pm), or ecotropic (E).
DOI: 10.1371/journal.ppat.0020025.g003
Figure 4. Multiple-Sequence Alignment of Protein Sequences from XMRV and Related MuLVs Spanning SU Glycoprotein VRA, VRB, and VRC, Known to
Determine Receptor Specificity
Env protein sequence from XMRV (identical in VP35, VP42, and VP62; red); MTCR; MuLVs DG-75, NZB-9–1, NFS-Th-1, MCF247, AKV, Moloney, Friend, and
Rauscher; and polytropic proviruses MX27 and MX33 [77] were aligned using ClustalX. Sequences are labeled as xenotropic (X), polytropic (P), modified
polytropic (Pm), or ecotropic (E). VRs are boxed. Dots denote residues identical to those from XMRV, and deleted residues appear as spaces.
DOI: 10.1371/journal.ppat.0020025.g004
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see above). The primers in this assay (Figure S1) amplify a
380-nt fragment from the divergent 59 leader and the N-
terminal end of gag. The RT-PCR was positive in eight (40%)
of 20 examined tumors from homozygous (QQ) individuals.
In addition, one tumor from a homozygous wild-type (RR)
patient was positive among 52 RR and 14 RQ tumors
examined (Figure 1 and Table 1). Interestingly, this case was
associated with the highest tumor grade among all XMRV-
positive cases (Table S3). PCR speciﬁc for the mouse GAPDH
gene was negative in all samples (unpublished data), arguing
strongly against the possibility that the tumor samples were
contaminated with mouse nucleic acid. Collectively, these
data demonstrate a strong association between the homo-
zygous (QQ) R462Q RNASEL genotype and presence of the
virus in the tumor tissue (p , 0.00002 by two-tail Fisher’s
exact test).
XMRV Sequence Diversity in Samples from Different
Patients
To examine the degree of XMRV sequence diversity in
different patients, we sequenced the ampliﬁed fragments
from all nine samples, which were positive by the nested gag
RT-PCR. The ampliﬁed gag fragments were highly similar
(Figure 6A) with .98% nt and .98% aa identity to each
other. In contrast, the fragments had ,89% nt and ,95% aa
identity with the most related exogenous sequence of MuLV
DG-75. Several corresponding endogenous non-ecotropic
sequences were more similar to the XMRV fragments,
including the xenotropic provirus from M. musculus Chro-
mosome 9, which was ,98% identical on the nt level.
Nevertheless, all XMRV-derived fragments were more similar
to each other than they were to any other sequence.
In addition to the gag gene, we also examined the same
patient samples for sequence variation in the pol gene. We
sequenced PCR fragments obtained with a set of primers
targeting a 2500-nt stretch in the pol gene (Figure S1). Similar
to the gag fragments, the ampliﬁed pol fragments were highly
similar (Figure 6B) and had .97% nt and .97% aa identity
to each other. In contrast, the fragments had ,94% nt and
,95% aa identity with the most related sequence, that of
MuLV DG-75. Interestingly, XMRV-derived pol sequences
were less similar to and approximately equidistant from the
examined representative xenotropic and polytropic endoge-
nous sequences.
Close clustering of the sequenced gag and pol fragments
(Figure 6) indicates that all microarray and RT-PCR positive
cases represent infection with the same virus. On the other
hand, the degree of sequence variation in the examined
Figure 5. Multiple-Sequence Alignment of 59 gag Leader Nucleotide Sequences from XMRV and Related MuLVs
Sequences extending from the alternative CUG start codon to the AUG start codon (underlined) of gag derived from XMRV VP35, VP42, and VP62 (blue);
MTCR, MuLVs DG-75, and Friend; and a set of representative non-ecotropic proviruses (mERVs) were aligned with ClustalX (see Materials and Methods).
Predicted amino acid translation corresponding to the VP35 sequence is shown above the alignment (red); asterisk indicates a stop. Sequences are
labeled as xenotropic (X), polytropic (P), modified polytropic (Pm), or ecotropic (E). Dots denote nt identical to those from XMRV, and deleted nt appear
as spaces.
DOI: 10.1371/journal.ppat.0020025.g005
Table 1. XMRV Screening by gag Nested RT-PCR
PCR RNASEL Genotype
a Total
QQ RQ RR
PCR þ 801 9
PCR   12 14 51 77
Total 20 14 52 86
aRNASEL genotypes are as follows: QQ, homozygous R462Q variant; RQ, heterozygous; RR,
homozygous wild-type.
DOI: 10.1371/journal.ppat.0020025.t001
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duced during PCR ampliﬁcation and sequencing. The
frequency of nt misincorporation by Taq polymerase has
been estimated as 10
 6   10
 4 ([63] and references therein),
compared with the observed rate of up to 2% in the gag and
pol fragments. These ﬁndings suggest that the observed XMRV
sequence variation is a result of natural sequence diversity,
consistent with the virus being independently acquired by the
affected patients, and argue against laboratory contamina-
tion as a possible source of XMRV.
Detection of XMRV in Tumor-Bearing Prostatic Tissues
Using FISH
To localize XMRV within human prostatic tissues, and to
measure the frequency of the infected cells, XMRV nucleic
acid was visualized using FISH on formalin-ﬁxed prostate
tissues. A SpectrumGreen ﬂuorescently labeled FISH probe
cocktail spanning all viral genes was prepared using cDNA
derived from the XMRV isolate cloned from patient VP35
(Materials and Methods). Distinct FISH-positive cells were
observed in the tumors positive for XMRV by RT-PCR (e.g.,
VP62 and VP88) (Figure 7). To identify cell types associated
with the positive FISH signal, the same sections were
subsequently stained with hematoxylin and eosin (H&E).
Most FISH-positive cells were stromal ﬁbroblasts (Figure 8A),
including those undergoing cell division (Figure 8B). In
addition, occasional infected hematopoietic cells were also
seen (Figure 8C). XMRV FISH with concurrent immunostain-
ing for cytokeratin AE1/AE3 to achieve speciﬁc labeling of
epithelial cells [64] showed no XMRV-infected cells that also
had the epithelium-speciﬁc staining, conﬁrming their non-
epithelial origin (Figure 8C). While the XMRV nucleic acid
was usually present within nuclei (Video S1), suggesting
integrated proviral DNA, some cells showed cytoplasmic
staining adjacent to the nucleus, suggestive of viral mRNA
and/or pre-integration complexes in non-dividing cells
(Figure 8A).
We also used FISH to obtain a minimal estimate of the
frequency of XMRV-infected prostatic cells. For this purpose
we employed a tissue microarray containing duplicates of 14
different prostate cancer tissue specimens (Table 2). FISH
with DNA probes derived from XMRV VP35 showed ﬁve to
ten XMRV/FISH–positive cells (about 1% of prostate cells
observed) in each of ﬁve homozygous RNase L 462Q (QQ)
cases: VP29, 31, 42, 62, and 88. Patient sample VP79, also a
QQ case, contained two positive cells (0.4% of total cells
examined). All of the XMRV/FISH–positive cells observed
were stromal cells. In contrast, three RR tissue samples and
two RQ tissue samples showed one or no (,0.15%) FISH-
positive cells. Two of the QQ cases, VP35 and VP90, positive
by gag RT-PCR, showed only one FISH-positive cell each
(Table 2). Conversely, one case, VP31, was FISH-positive, but
gag–RT-PCR negative. As expected, Chromosome 1–speciﬁc
probes used as a positive control speciﬁcally labeled nearly
every cell from the examined case VP88, whereas a KSHV-
speciﬁc probe used as a negative control did not label any
cells in sections from cases VP88 and VP51, but did efﬁciently
label 293T cells transfected with KSHV DNA (unpublished
data). Thus, consistent with the microarray and RT-PCR data,
detection of XMRV by FISH was associated primarily with
QQ cases. In addition, in samples where XMRV was detected,
all positive cells were stromal and did not account for more
than 1% of all prostatic cells. Finally, differences in the
numbers of XMRV-positive cells detected in the different
samples could be due to heterogeneity in virus copy numbers
between different patients and/or speciﬁc regions of the
prostate sampled.
Figure 6. Comparison of XMRV Sequences Derived from Tumor Samples of Different Patients
(A) Phylogenetic tree based on the 380 nt XMRV gag RT-PCR fragment from the nine positive tumor samples (red) and the corresponding sequences
from MTCR; MuLVs DG-75, MCF1233, Akv, Moloney, Rauscher and Friend; and a set of representative non-ecotropic proviruses (mERVs). The sequences
were aligned using ClustalX, and the corresponding tree was generated using the neighbor-joining method (see Materials and Methods). Bootstrap
values (n¼1000 trials) are indicated as percentages. Sequences are labeled as xenotropic (X), polytropic (P), modified polytropic (Pm), or ecotropic (E).
(B) Phylogenetic tree based on a 2500-nt pol PCR fragment from the 9 XMRV-positive tumor samples. The tree was constructed as described in (A).
DOI: 10.1371/journal.ppat.0020025.g006
PLoS Pathogens | www.plospathogens.org March 2006 | Volume 2 | Issue 3 | e25 0217
Virus in Prostate Tumors with R462Q RNASELDetection of XMRV in Tumor-Bearing Prostatic Tissues
Using IHC
To identify cells expressing XMRV proteins, we assayed for
the presence of Gag protein using a monoclonal antibody
against (SFFV); this antibody is reactive against Gag proteins
from a wide range of different ecotropic, polytropic, and
xenotropic MuLV strains [65]. Using this antibody, positive
signal by IHC was observed in prostatic tissues of XMRV-
positive cases VP62 and VP88, both QQ (Figure 9). An
enhanced alkaline phosphatase red detection method allowed
Gag detection in the same cells with both ﬂuorescence (Figure
9A–9D, left) and bright ﬁeld (Figure 9A–9D, middle) micro-
scopy. The Gag-expressing cells were observed in prostatic
stromal cells with a distribution and frequency similar to that
detected by FISH (Figure 9 and unpublished data). In
contrast, no Gag-positive cells were observed in VP51
prostatic tissue, which is of RR genotype (Figure 9E).
Discussion
The results presented here identify XMRV infection in
prostate tissue from approximately 40% of patients with
prostate cancer who are homozygous for the R462Q variant
(QQ) of RNase L, as judged by both hybridization to the
Virochip microarray and by RT-PCR with XMRV-speciﬁc
primers. Parallel RT-PCR studies of prostate tumors from
wild-type (RR) and heterozygous (RQ) patients revealed
evidence of XMRV in only one of 66 samples, clearly
demonstrating that human XMRV infection is strongly linked
to decrements in RNase L activity. This result supports the
view that the R462Q RNase L variant leads to a subtle defect
in innate (IFN-dependent) antiviral immunity.
As its name indicates, XMRV is closely related to
xenotropic murine leukemia viruses (MuLVs). Unlike eco-
tropic MuLVs, such as the canonical Moloney MuLV, which
grow only in rodent cells in culture, xenotropic MuLVs can
grow in non-rodent cells in culture but not in rodent cell
lines. Xenotropic viruses have been isolated from many
inbred as well as wild mouse strains. Studies of the
distribution of non-ecotropic sequences in different mouse
strains show that the diversity of xenotropic proviral
sequences in wild mice is greater than that found in the
inbred laboratory strains [49,66]. This ﬁnding led to the
conclusion that these endogenous elements were independ-
ently and relatively recently acquired by different mouse
species as a result of infection rather than inheritance [49].
Unlike ecotropic MuLVs, which can only recognize a receptor
(CAT-1) speciﬁc to mouse and rat species [67–69], xenotropic
Figure 7. Detection of XMRV Nucleic Acid in Prostatic Tissues Using FISH
Prostatic tumor tissue sections from QQ cases VP62 (A–C) and VP88 (D–F) were analyzed by FISH using DNA probes (green) derived from XMRV VP35
(top right enlargements). Nuclei were counterstained with DAPI. The same sections were then visualized by H&E staining (left panels). Scale bars are 10
lm. Arrows indicate FISH positive cells, and their enlarged images are shown in the bottom right panels.
DOI: 10.1371/journal.ppat.0020025.g007
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expressed in all higher vertebrates, including mice, but
polymorphisms in the murine gene render it unable to
mediate xenotropic MuLV entry [38–40]. Thus, xenotropic
M u L V sh a v eap o t e n t i a lt oi n f e c taw i d ev a r i e t yo f
mammalian species, including humans.
Xenotropic MuLVs have occasionally been detected in
cultured human cell lines. For example, MuLV DG-75 was
cloned from a human B-lymphoblastoid cell line [24], and an
infectious xenotropic MuLV was detected in a human small
cell lung cancer line NCI-417 [32]. Although laboratory
contamination, either in culture or during passage of cell
lines in nude mice, cannot be ruled out as a possible source in
these cases, such contamination cannot explain our results.
The evidence for this is as follows: (i) XMRV was detected in
primary human tissues; (ii) no murine sequences (e.g.,
GAPDH) could be detected in our materials by PCR; (iii)
infection was predominantly restricted to human samples
with the QQ RNASEL genotype; (iv) polymorphisms were
found in the XMRV clones recovered from different patients
consistent with independent acquisition of the virus by these
individuals; and (v) viral nucleic acids and antigens could be
detected in infected QQ prostate tissue by FISH and IHC,
respectively. Taken together, the above evidence argues
strongly against laboratory contamination with virus or
cloned DNA material as the source of XMRV infection in
the analyzed samples. To our knowledge, this report
represents the ﬁrst published examples of authentic infection
Figure 8. Characterization of XMRV-Infected Prostatic Cells by FISH and FISH/Immunofluorescence
Using a tissue microarray, prostatic tumor tissue sections from QQ case VP62 were analyzed by FISH (green) using DNA probes derived from XMRV VP35
(left panels). Nuclei were counterstained with DAPI. The same sections were then visualized by H&E staining (middle panels). Arrows indicate FISH-
positive cells, and their enlarged FISH and H&E images are shown in the top right and bottom right panels, respectively. Scale bars are 10 lm.
(A) A stromal fibroblast.
(B) A dividing stromal cell.
(C) A stromal hematopoietic cell. The section was concomitantly stained for XMRV by FISH (green) and cytokeratin AE1/AE3 by immunofluorescence
(red).
DOI: 10.1371/journal.ppat.0020025.g008
PLoS Pathogens | www.plospathogens.org March 2006 | Volume 2 | Issue 3 | e25 0219
Virus in Prostate Tumors with R462Q RNASELof humans with a xenotropic MuLV-like agent. Although our
efforts to clone the sites of XMRV integration into the host
genome have been limited by the small amounts of prostate
tissue available for this purpose, our work to clone such sites
is ongoing and will provide an important additional piece of
evidence for XMRV infection in humans.
The XMRV sequence is not found in human genomic DNA,
and none of the human endogenous retroviruses, including
the only known gammaretrovirus-like human endogenous
sequences (hERVs E and T) [70], bare any signiﬁcant similarity
to the XMRV genome. This indicates that XMRV must have
been acquired exogenously by infection in positive subjects.
From what reservoir and by what route such infections were
acquired is unknown. It seems unlikely that direct contact
with feral mice could explain the observed distribution of
infection in our cohort, since there is no reason to believe
that rodent exposure would vary according to RNASEL
genotype. It is possible that infection is more widespread
than indicated by the present studies, especially if, as seems
likely, individuals with the wild-type RNase L clear infection
more promptly than those with the QQ genotype. But if so, a
cross-species transfer model of XMRV infection would
require improbably high levels of rodent exposure for a
developed society like our own. Thus, although the viral
sequence suggests that the ultimate reservoir of XMRV is
probably the rodent, the proximate source of the infection
seems unlikely to be mice or rats. Provisionally, we favor the
notion that the XMRV infections we have documented were
acquired from other humans, i.e., that XMRV may have been
resident in the human population for some time. This
speculation will, however, require direct epidemiologic
validation. It also remains to be determined if RNase L
R462Q homozygotes are more sensitive to the acquisition of
infection, or are simply less likely to clear infection once
acquired. This is an important issue, since if the latter model
is correct, it would imply that in younger humans, XMRV
prevalence may be higher than what is observed in our
prostate cancer cohort (mean age 58.7 y). We are currently
developing serologic assays for use in population-based
studies that should shed light on these matters.
While presented work documents a clear link of XMRV
infection to RNase L deﬁciency, we emphasize that the data
we have accumulated does not mandate any etiological link to
prostate cancer. Furthermore, our ﬁnding that XMRV
infection is targeted to stromal cells and not to carcinoma
cells and the fact that the XMRV genome harbors no host-
derived oncogenes rule out two classical models for retroviral
oncogenesis: direct introduction of a dominantly acting
oncogene and insertional activation of such a gene. However,
more indirect contributions of the virus to the tumor can
certainly be envisioned. Recent work has shown that stromal
cells have an active role in directly promoting tumorigenesis
of adjacent epithelial cells by producing various cytokines
and growth factors that serve as proliferative signals [71] or
indirectly by modifying the tumor microenvironment by
promotion of angiogenesis or recruitment of inﬂammatory
mediators leading to oxidative stress [72]. In particular,
cancer-associated ﬁbroblasts stimulate growth of human
prostatic epithelial cells and alter their histology in vivo
[73]. It is conceivable that XMRV-infected prostatic stromal
cells could produce and secrete growth factors, cytokines or
other factors that stimulate cell proliferation or promote
oxidative stress in surrounding epithelia. Such a paracrine
mechanism could still function quite efﬁciently even with the
relatively small number of XMRV-infected cells that charac-
terize the lesion.
Finally, we note that the identiﬁcation of an exogenous
infection such as XMRV could help explain why not all
genetic studies have consistently identiﬁed RNase L as a
prostate cancer susceptibility factor. If such an infection were
linked, however indirectly, to prostate cancer risk, and if the
prevalence of infection is not uniform in different popula-
tions, populations with low XMRV prevalence might be
expected to show no association of RNASEL lesions to
prostate cancer.
Clearly, resolution of these issues will require much further
investigation. We need to determine the prevalence of XMRV
Table 2. Frequency of XMRV-Infected Prostatic Cells Determined by FISH
Patient RNASEL Genotype
a Number of Cells Counted
b Number of FISH-Positive Cells (%) XMRV FISH
c XMRV gag RT-PCR
VP 88 QQ 408 5 (1.23) þþ þ
VP 31 QQ 526 6 (1.14) þþ  
VP 42 QQ 530 6 (1.13) þþ þ
VP 62 QQ 904 10 (1.11) þþ þ
VP 29 QQ 659 7 (1.06) þþ þ
VP 79 QQ 464 2 (0.43) þþ
VP 10 QQ 872 1 (0.12) þ/  
VP 35 QQ 849 1 (0.12) þ/ þ
VP 90 QQ 843 1 (0.12) þ/ þ
VP 45 RQ 987 0 (0)   
VP 46 RQ 794 0 (0)   
VP 30 RR 661 1 (0.15) þ/  
VP 50 RR 787 1 (0.13) þ/  
VP 51 RR 842 0 (0)   
aRNASEL genotypes are as follows: QQ, homozygous R462Q variant; RQ, heterozygous; RR, homozygous wild-type.
bAll types of prostatic cells are included.
cþ/ ¼0.1%–0.2%; þ¼0.2% 1%; þþ ¼ .1%.
DOI: 10.1371/journal.ppat.0020025.t002
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transmission and tissue tropism, explore its associations with
pre-maligant and other prostatic conditions, and deﬁne the
biochemical interactions of the virus with the 2–5A/RNase L
system. The availability of molecular clones, infectious virus
stocks, and susceptible cell culture systems should greatly
enhance our ability to probe these and other questions in the
near future.
Materials and Methods
Genotyping of patients, and prostate tissue processing. All human
samples used in this study were obtained according to protocols
approved by the Cleveland Clinic’s Institutional Review Board. Age,
clinical parameters, and geographical locations of XMRV-positive
prostate cancer cases are provided in Table S3. Men scheduled to
undergo prostatectomies at the Cleveland Clinic were genotyped for
the R462Q (1385G-.A) RNASEL variant using a premade TAQMAN
genotyping assay (Applied Biosystems, Foster City, California, United
States; Assay c_935391_1) on DNA isolated from peripheral blood
mononuclear cells. Five nanograms of genomic DNA were assayed
according to the manufacturer’s instructions, and analyzed on an
Applied Biosystems 7900HT Sequence Detection System instrument.
Immediately after prostatectomies, tissue cores were taken from both
the transitional zone (the site of benign prostatic hyperplasia, BPH)
and the peripheral zone (where cancer generally occurs), snap-frozen
in liquid nitrogen, and then stored at  80 8C. Remaining prostate
tissue was ﬁxed in 10% neutral buffered formalin, processed, and
embedded in parafﬁn for later histological analyses. Frozen tissue
cores were transferred from dry ice immediately to TRIZOL reagent
(Invitrogen, Carlsbad, California, United States), homogenized with a
power homogenizer or manually using a scalpel followed by a syringe,
and total RNA was isolated according to the manufacturer’s
instructions. The prostate tissue RNA was then subjected to RNase-
free DNase I (Ambion, Austin, Texas, United States) digestion for 30
min at 37 8C. The sample was then extracted with phenol and the
RNA was precipitated with isopropanol overnight at 20 8C followed
by centrifugation at 12,000 g for 30 min at 4 8C. Poly-A RNA was
isolated from the DNase digested total RNA using the Oligotex
mRNA Midi Kit (Qiagen USA, Valencia, California, United States) as
instructed by the manufacturer. The poly-A RNA concentration was
measured using the RIBOgreen quantitation kit (Molecular Probes,
Invitrogen), and the samples were stored at  80 8C.
Microarray screening. Virochip microarrays used in this study were
identical to those previously described [20–22]. Prostate tumor RNA
samples were ampliﬁed and labeled using a modiﬁed Round A/B
random PCR method and hybridized to the Virochip microarrays as
reported previously (Protocol S1 in [21]). Microarrays were scanned
with an Axon 4000B scanner (Axon Instruments, Union City,
California, United States) and gridded using the bundled GenePix
3.0 software. Microarray data have been submitted to the NCBI GEO
database (GSE3607). Hybridization patterns were interpreted using E-
Predict as previously described [22] (Table S1). To make Figure 1,
background-subtracted hybridization intensities of all retroviral
oligonucleotides (205) were used to cluster samples and the
oligonucleotides. Average linkage hierarchical clustering with Pear-
son correlation as the similarity metric was carried out using Cluster
(version 2.0) [74]. Cluster images were generated using Java TreeView
(version 1.0.8) [75].
Genome cloning and sequencing. Ampliﬁed and labeled cDNA
from the VP35 tumor sample was hybridized to a hand-spotted
microarray containing several retroviral oligonucleotides, which had
high hybridization intensity on the Virochip during the initial
microarray screening. Nucleic acid hybridizing to two of the
oligonucleotides (9628654_317_rc derived from MTCR: TTC GCT
TTA TCT GAG TAC CAT CTG TTC TTG GCC CTG AGC CGG GGC
CCA GGT GCT CGA CCA CAG ATA TCC T; and 9626955_16_rc
derived from SFFV: TCG GAT GCA ATC AGC AAG AGG CTT TAT
TGG GAA CAC GGG TAC CCG GGC GAC TCA GTC TGT CGG AGG
ACT G) was then individually eluted off the surface of the spots and
ampliﬁed by PCR with Round B primers. Preparation of the hand-
spotted array, hybridization, probe recovery, and PCR ampliﬁcation
of the recovered material were carried out according to Protocol S1.
The recovered ampliﬁed DNA samples were then cloned into pCR2.1-
TOPO TA vector (Invitrogen), and the resulting libraries were
screened by colony hybridization with the corresponding above
oligonucleotides as probes. Hybridizations were carried out using
Rapid-Hyb buffer (Amersham, Piscataway, New Jersey, United States)
according to the manufacturer’s protocol at 50 8C for 4 h. Eight
positive clones were sequenced, of which two (one from each library;
clones K1 and K2R1 in Figure 2A) were viral and had 94–95% nt
identity to MTCR.
To sequence the remainder of the VP35 genome as well as the
entire genome from the VP42 tumor, we ampliﬁed fragments of the
genome by PCR using either ampliﬁed (Round B) or unampliﬁed
Figure 9. Detection of XMRV Protein in Prostatic Tissues Using
Immunostaining
Prostatic tumor tissue sections from QQ cases VP62 (A and B) and VP88
(C and D), as well as an RR case VP51 (E) were stained, then visualized by
immunofluorescence (left) or bright field (middle) using a monoclonal
antibody to SFFV Gag protein. Nuclei are counterstained with
hematoxylin. Enlarged images corresponding to the positive cells are
shown on the right. Scale bars are 5 lm in (A), (B), and (E) and 10 lmi n
(C) and (D).
DOI: 10.1371/journal.ppat.0020025.g009
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accomplished ﬁrst using a combination of primers derived from the
sequence of MTCR and earlier recovered clones of XMRV. The two
overlapping fragments from VP62 were ampliﬁed by PCR from cDNA
generated by priming poly-A RNA with random hexamers. All PCR
primers are listed in Table S2. The ampliﬁed fragments were cloned
into pCR2.1-TOPO TA vector (Invitrogen) and sequenced using M13
sequencing primers. Genome assembly was carried out using
CONSED version 13.84 for Linux [76].
PCR. Screening of tumor samples by gag nested RT-PCR was
carried out according to Protocol S2. PCR fragments in all positive
cases were gel-puriﬁed using QIAEX II gel extraction kit (Qiagen),
cloned into pCR2.1-TOPO TA vector (Invitrogen), and sequenced
using M13 sequencing primers.
Pol PCR was carried out using ampliﬁed cDNA (Round B material)
as the template.
Sequence of the primers used for ampliﬁcation (2670F, 3870R,
3810F, and 5190R) is listed in Table S2. Ampliﬁed products were gel-
puriﬁed using QIAEX II gel extraction kit (Qiagen), and puriﬁed
products were directly used for sequencing.
Phylogenetic analyses. Xenotropic mERV Chromosome 1, xeno-
tropic mERV Chromosome 4, and xenotropic mERV Chromosome 9
were chosen by BLAST querying the NCBI nr database with the
complete XMRV genomes and selecting the most similar full-length
proviral sequences, all of which happened to have xenotropic
envelopes (Figure S2C). Polytropic mERV Chromosome 7 and
polytropic mERV Chromosome 11 were chosen by selecting NCBI
nr full-length proviral sequences with envelopes most similar to a
prototype polytropic clone MX27 [77]. Similarly, modiﬁed polytropic
mERV Chromosome 7 and modiﬁed polytropic mERV Chromosome
12 were selected on the basis of similarity to a prototype-modiﬁed
polytropic clone MX33 [77]. U3 analysis was performed using
previously described reference sequences: Mcv18, Mcv3, Mxv2,
Mcv11, Mxv11, and HEMV18 [49]; CWM-T-15, CWM-T-15–4, CWM-
T-25a, and CWM-T-25b [48].
To generate the neighbor-joining tree of complete genomic
sequences (Figure 3), the sequences were ﬁrst manually edited to
make all genomes the same length, i.e., R to R. The edited sequences
were then aligned with ClustalX version 1.82 for Linux [78,79] using
default settings. The tree was generated based on positions without
gaps only; Kimura correction for multiple base substitutions [80] and
bootstrapping with n ¼ 1000 were also used.
All other trees were generated as above, except sequences were
ﬁrst trimmed to the same length, gaps were included, and Kimura
correction was not used, as using these parameters did not have any
signiﬁcant effect on the trees.
Antibodies. Monoclonal antibody to SFFV Gag protein was
produced from R187 cells ([65]; ATCC: CRL-1912) grown in DMEM
(Media Core, Cleveland Clinic Foundation, Cleveland, Ohio, United
States) with 10% ultra-low IgG FBS (Invitrogen) until conﬂuent.
Conditioned media was collected every three days from conﬂuent
cultures. Five ml of conditioned media per preparation was
centrifuged at 168 3 g for 5 min at 4 8C. Supernatant was ﬁltered
through a 0.22-lm syringe ﬁlter unit (Millipore, Billerica, Massachu-
setts, United States) and concentrated 16-fold in an Amicon ultra-
ﬁltration unit with a 100-kDa molecular weight cutoff membrane
(Millipore). Sodium azide was added to a ﬁnal concentration of
0.02%. Concomitant XMRV FISH/cytokeratin immunoﬂuorescence
was performed using a mouse anti-cytokeratin AE1/AE3 (20:1
mixture) monoclonal antibody (Chemicon International, Temecula,
California, United States) capable of recognizing normal and
neoplastic cells of epithelial origin.
FISH. The XMRV-35 FISH probe cocktail was generated using both
2.15-kb and 1.84-kb segments of the viral genome obtained by PCR
with forward primer-2345, 59 ACC CCT AAG TGA CAA GTC TG 39
with reverse primer-4495, 59 CTG GAC AGT GAA TTA TAC TA 39
and forward primer-4915, 59 AAA TTG GGG CAG GGG TGC GA 39
with reverse primer-6755, 59 TTG GAG TAA GTA CCT AGG AC 39,
both cloned into pGEM-T (Promega, Madison, Wisconsin, United
States). The recombinant vectors were digested with EcoRI to release
the viral cDNA fragments, which were puriﬁed after gel electro-
phoresis (Qiagen). The puriﬁed viral cDNA inserts were used in nick
translation reactions to produce SpectrumGreen dUTP ﬂuorescently
labeled probe according to manufacturer’s instructions (Vysis Inc.,
Des Plaines, Illinois, United States). Freshly baked slides of prostatic
tissues or tissue microarray arrays with ;4-lm thick tissue sections
were deparafﬁnized, rehydrated, and subjected to Target Retrieval
(Dako, Glostrup, Denmark) for 40 min at 95 8C. Slides were cooled to
room temperature and rinsed in H2O. Proteinase K (Dako) at 1:5000
in Tris-HCl (pH 7.4) was applied directly to slides for 10 min at room
temperature. Adjacent tissue sections were also probed with
SpectrumGreen dUTP ﬂuorescently labeled KSHV-8 DNA (nts
85820–92789) as a negative control or, as a positive control with
SpectrumGreen and SpectrumOrange labeled TelVysion DNA Probe
cocktail (Vysis), speciﬁc for subtelomeric regions of the P and Q arms
of human Chromosome 1 as a positive control to ensure the tissue
was completely accessible to FISH. FISH slides were examined using a
Leica DMR microscope (Leica Micro-Systems, Heidelberg, Germany),
equipped with a Retiga EX CCD camera (Q-Imaging,Vancouver,
British Columbia, Canada). FISH images were captured using a Leica
TCS SP2 laser scanning confocal with a 633 oil objective numerical
aperature 1.4 (Leica Micro-Systems) microscope. XMRV nucleic acids
were visualized using maximum intensity projections of optical slices
acquired using a 488-nm argon-laser (emission at 500–550 nm).
TelVysion DNA Probes were visualized using maximum intensity
projections of optical slices acquired using a 488-nm argonlaser
(emission at 500–550 nm) and 568-nm krypton-argon-laser (emission
at 575–680 nm). DAPI was visualized using maximum intensity
projections of optical slices acquired using a 364–nm UV-laser
(emission at 400–500 nm). Slides were subsequently washed in 23SSC
(0.3 M sodium chloride and 0.03 M sodium citrate, [pH 7.0]) to
remove coverslips, and H&E stained for morphological evaluation.
IHC. IHC on human tissues was performed on a Benchmark
Ventana Autostainer (Ventana Medical Systems, Tucson, Arizona,
United States). Unstained, formalin-ﬁxed, parafﬁn-embedded pros-
tate sections were placed on electrostatically charged slides and
deparafﬁnized followed by a mild cell conditioning achieved through
the use of Cell Conditioner #2 (Ventana Medical Systems). The
concentrated R187 monoclonal antibody against SFFV p30 Gag was
dispensed manually onto the sections at 10 lg per ml and allowed to
incubate for 32 min at 37 8C. Endogenous biotin was blocked in
sections using the Endogenous Biotin Blocking Kit (Ventana Medical
Systems). Sections were washed, and biotinylated ImmunoPure Goat
Anti-Rat IgG (Pierce Biotechnology, Rockford, Illinois, United States)
was applied at a concentration of 4.8 lg per ml for 8 min. To detect
Gag protein localization, the Ventana Enhanced Alkaline Phospha-
tase Red Detection Kit (Ventana Medical Systems) was used. Sections
were brieﬂy washed in distilled water and counterstained with
Hematoxylin II (Ventana Medical Systems) for approximately 6
min. Sections were washed, dehydrated in graded alcohols, incubated
in xylene for 5 min, and coverslips were added with Cytoseal (Microm
International, Walldorf, Germany). Negative controls were performed
as above except without the addition of the R187 monoclonal
antibody.
Concomitant XMRV FISH/cytokeratin IHC was performed on
slides of prostate tissue from patient VP62. First, sections were
immunostained for cytokeratin AE1/AE3 using the Alexa Fluor 594
Tyramide Signal Ampliﬁcation Kit (Molecular Probes, Invitrogen).
Brieﬂy, unstained, formalin-ﬁxed, parafﬁn-embedded sections cut at
;4 lm were placed on electrostatically charged slides, baked at 65 8C
for at least 4 h, deparafﬁnized in xylene, and rehydrated through
decreasing alcohol concentrations. Slides were incubated in Protease
II (Ventana Medical Systems) for 3 min at room temperature and
washed in phosphate-buffered saline (PBS) in peroxidase quenching
buffer (PBS þ 3% H2O2) for 60 min at room temperature, then
incubated with 1% blocking reagent (10 mg/ml BSA in PBS) for 60
min at room temperature. The slides were incubated with cytokeratin
AE1/AE3 antibody diluted in 1% blocking reagent for 60 min at room
temperature and rinsed 33 times in PBS. Goat anti-mouse IgG-
horseradish peroxidase (Molecular Probes, Invitrogen) was added and
incubated for 60 min at room temperature. The slides were rinsed 33
in PBS. The tyramide solution was added to the slides for 10 min at
room temperature and the slides were rinsed 33 in PBS. Slides were
then placed in Target Retrieval solution (Dako) for 40 min at 95 8C.
FISH for XMRV was performed as described above except in the
absence of proteinase K treatment. After FISH, the slides were
mounted with Vectashield Mounting Medium plus DAPI (Vector
Labs, Burlingame, California, United States) and examined using
ﬂuorescence microscopy. Immunoﬂuorescence images were captured
using a Texas red ﬁlter with a Leica DMR microscope (Leica Micro-
Systems), equipped with a Retiga EX CCD camera (QImaging).
Supporting Information
Figure S1. Complete Nucleotide Sequence of XMRV VP35
Numbers to the left indicate nt coordinates relative to the ﬁrst nt.
Predicted open reading frames for Gag, Gag-Pro-Pol, and Env
polyproteins are shown below the corresponding nt. Characteristic
24-nt deletion in the 59 gag leader is indicated with a triangle. Other
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Virus in Prostate Tumors with R462Q RNASELgenome features as well as primers used in the nested gag RT-PCR are
shown as arrows.
Found at DOI: 10.1371/journal.ppat.0020025.sg001 (558 KB PDF).
Figure S2. Phylogenetic Analysis of XMRV Based on Predicted Gag,
Pro-Pol, and Env Polyproteins
Predicted Gag (A), Pro-Pol (B), and Env (C) sequences of XMRV VP35,
VP42, and VP62 (red) as well as the corresponding sequences from
M T C R ;M u L V sD G - 7 5 ,M C F 1 2 3 3 ,A k v ,M o l o n e y ,F r i e n d ,a n d
Rauscher; feline leukemia virus (FLV); koala retrovirus (KoRV);
gibbon ape leukemia virus (GALV), and a set of representative non-
ecotropic proviruses (mERVs) were aligned using ClustalX. The
resulting alignments were used to generate unrooted neighbor-
joining trees (see Materials and Methods). Sequences are labeled as
xenotropic (X), polytropic (P), modiﬁed polytropic (Pm), or ecotropic
(E).
Found at DOI: 10.1371/journal.ppat.0020025.sg002 (186 KB EPS).
Figure S3. Comparison of XMRV U3 Region to Representative Non-
Ecotropic Sequences
(A) Multiple sequence alignment of U3 sequences from XMRV VP35,
VP42, and VP62; MuLVs NZB-9–1 and NFS-Th-1; and from
representative non-ecotropic proviruses [37,48,49]. The sequences
were aligned using ClustalX (see Materials and Methods). Only
sequences most similar to XMRV are shown. Glucocorticoid response
element (GRE), and TATA and CAT boxes are indicated by lines.
Direct repeat regions (boxed) are numbered according to the existing
convention [37,49]. Triangle indicates a 190 nt insertion in polytropic
proviruses [37]. XMRV-speciﬁc AG dinucleotide insertion is shown in
red. Dots denote nt identical to those from XMRV, and deleted nt
appear as spaces.
(B) Phylogenetic tree based on U3 nt sequences. Multiple sequence
alignment from (A) was used to generate an unrooted neighbor-
joining tree (see Materials and Methods). Bootstrap values (n ¼ 1000
trials) are shown as percentages. U3 sequences from XMRV are shown
in red.
Found at DOI: 10.1371/journal.ppat.0020025.sg003 (188 KB EPS).
Protocol S1. Probe Recovery from Hand-Spotted Microarrays by
‘‘Scratching’’
Found at DOI: 10.1371/journal.ppat.0020025.sd001 (83 KB PDF).
Protocol S2. XMRV gag Nested RT-PCR
Found at DOI: 10.1371/journal.ppat.0020025.sd002 (172 KB PDF).
Table S1. Computational Viral Species Predictions Using E-Predict
for the Virochip Microarrays Shown in Figure 1
Found at DOI: 10.1371/journal.ppat.0020025.st001 (48 KB DOC).
Table S2. PCR Primers Used for Sequencing of XMRV Genomes
Found at DOI: 10.1371/journal.ppat.0020025.st002 (45 KB DOC).
Table S3. Age, Clinical Parameters, and Geographical Locations of
XMRV-Positive Prostate Cancer Cases
Found at DOI: 10.1371/journal.ppat.0020025.st003 (39 KB DOC).
Video S1. Confocal Optical Image Planes of a Representative XMRV
FISH Positive Cell
Optical image planes (0.5 lm step-size) of the XMRV FISH positive
cell from Figure 1A acquired using a Leica TCS SP2 laser scanning
spectral confocal microscope (Leica, Heidelberg, Germany) were
reconstructed into a 3D volume set using Volocity 3.5 (Improvision,
Lexington, Massachusetts, United States). Using Volocity’s movie
sequence editor, each volume was rotated along horizontal and
vertical axes, adjusting nuclei stained DAPI (blue) channel brightness
to visualize underlying XMRV FISH (green) nucleic acid signal. The
resulting image frames were exported as a movie sequence. Under-
lying grid represents glass slide to which tissue was placed for FISH
analysis. Each square unit within grid represents 4 lm in height and
width.
Found at DOI: 10.1371/journal.ppat.0020025.sv001 (237 KB WMV).
Accession Numbers
Accession numbers from Gen Bank (http://www.ncbi.nlm.nih.gov/
Genbank) are: AKV MuLV (J01998), feline leukemia virus
(NC_001940), Friend MuLV (NC_001372), gibbon ape leukemia
virus (NC_001885), koala retrovirus (AF151794), modiﬁed polytropic
mERV Chromosome 7 (AC127565; nt 64,355–72,720), modiﬁed
polytropic mERV Chromosome 12 (AC153658; nt 85,452–93,817),
Moloney MuLV (NC_001501), MTCR (NC_001702MuLV DG-75
(AF221065); MuLV MCF 1233 (U13766), MuLV NCI-417 (AAC97875),
MuLV NZB-9–1 (K02730), polytropic mERV Chromosome 7
(AC167978; nt 57,453–65,805), polytropic mERV Chromosome 11
(168–229,176,580), prototype polytropic clone MX27 (M17327),
Rauscher MuLV (NC_001819), xenotropic mERV Chromosome 1
(AC083892, nt 158,240–166,448), xenotropic mERV Chromosome 4
(AL627077; nt 146,400–154,635), xenotropic mERV Chromosome 9
(AC121813; nt 37,520–45,770), XMRV VP35 (DQ241301), XMRV VP42
(DQ241302), and XMRV VP 62 (DQ399707).
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